SUMMARY To establish whether concentrations of eicosanoids determined by equilibrium in vivo dialysis of faeces and equilibrium in vivo dialysis of rectum might predict a relapse in ulcerative colitis, 23 patients with completely inactive disease, maintained on sulphasalazine, stopped treatment and entered a prospective study. Concentrations of prostaglandin E2 were determined by radioimmunoassay on purified faecal and rectal dialysates at entry, at two weeks, and at two, six, and 12 months. If the above concentrations exceeded control concentrations (0'5 nglml and 1.0 ng/ml in faecal and rectal fluid, respectively) at any study day, the patient was allocated at random to double blind treatment with sulphasalazine 2 g/day, or placebo for six months. A relapse, defined as recurrence of symptoms accompanied by endoscopic inflammation occurred in none of six and in four of five patients allocated to sulphasalazine and placebo, respectively (p<005). In no case a normal rectal prostaglandin E2 concentration was associated with a relapse in the short term, but only two of 12 patients observed passively remained in remission. In retrospect, leucotriene B4 was a less sensitive predictor of relapse than prostaglandin E2. We conclude that raised concentrations of prostaglandin E2 in rectal dialysis fluid identify patients with a substantial risk of relapse.
Since it was originally reported in a controlled trial' that sulphasalazine (SAZ) reduces the recurrence rate in patients with ulcerative colitis (UC) this drug has become the mainstay of maintenance therapy for the prevention of relapse in patients with UC.2 1 The duration of SAZ therapy, given for more than one year, however, remains controversial and two early studies gave conflicting results.45 Despite several subsequent studies have shown higher relapse rates in patients discontinuing SAZ treatment for other remedies'9 current practice, as to how long to continue treatment, often rests on 'personal clinical experience' -also because no clinical or laboratory indices have been shown to improve decision making.
The concentration of prostaglandin E2 (PGE2) in rectal dialysis fluid, obtained by the method of equilibrium in vivo dialysis of rectum, was shown recently to be a sensitive marker of disease activity."' Furthermore, it was suggested that a rise in PGE2 concentrations in faecal dialysates, obtained by the method of equilibrium in vivo dialysis of faeces in patients with inactive UC, precedes the development of clinical symptoms in those who later experience a relapse." The purpose of the present study was to establish whether prospective determinations of PGE2 concentrations in faecal and rectal dialysis fluid, in patients with inactive UC discontinuing SAZ therapy, might predict a relapse and thus improve medical decision making. Patients with UC in complete remission, maintained on SAZ for at least one 316 Eicosanoids aspredictors ofrelapse in UC year, therefore, entered a double blind placebo controlled trial on the efficacy of SAZ, if PGE2 concentrations rose above control levels.
Methods

PATIENTS
Patients fulfilling the following entry criteria were candidates for the study: (a) proven UC on the basis of symptoms, endoscopic findings, histology of the rectal mucosa, and radiologic appearance, in addition to an exclusion of infectious diarrhoea by stool cultures and microscopy;'2 (b) inactive disease (remission) for at least 12 months during maintenance treatment with SAZ (Salazopyrin, Pharmacia AB, Uppsala, Sweden) 2 g/day. Patients were considered in remission when symptom-free -that is, stool frequency 2 x a day, without discharge of blood, pus, or mucus from the rectum, with normal sigmoidoscopic appearance, and with no significant inflammation on rectal biopsy.5'
The study was done in accordance with the Helsinki Declaration II and approved by the Ethical Committee of Funen and Vejle Counties. Informed consent was given by all participants.
EXPERIMENTAL DESIGN
Equilibrium in vivo dialysis of faeces as well as equilibrium in vivo dialysis of rectum were done in consenting patients fulfilling the entry criteria. Subsequently, SAZ was stopped and the patients were free of medication. Evaluation of clinical disease activity, in addition to sigmoidoscopy with rectal biopsies for assessing endoscopic and histologic disease activity,'0"3 were done at scheduled visits after two weeks, after two, six, and 12 months, and in between, if indicated by recurrence of colitic symptoms. A relapse was defined as a recurrence of colitic symptoms accompanied by endoscopic signs of inflammation. If a relapse occurred the patient was withdrawn. At the scheduled visits also in vivo dialysis measurements were carried out. If faecal PGE2 concentrations and/or rectal PGE2 concentrations exceeded control levels -that is, faecal PGE2 >0.5 ng/ml; rectal PGE2 >1*0 ng/ml -at any study day the patient was allocated at random to double blind maintenance treatment with SAZ (tablets 0-5 g; two tablets bid) or placebo tablets (two tablets bid) of identical appearance for six months. The SAZ and placebo tablets were provided by Pharmacia AB, Uppsala, Sweden. The randomisation was done according to a computer generated list in blocks of four, stratified for visit (two weeks, two months, six months, 12 months). In randomised patients a final visit was scheduled after six months of randomisation for in vivo dialysis measurements and for assessment of clinical, endoscopic, and histologic disease activity in case a relapse had not occurred earlier.
To minimise the variation between observers'4 each patient was examined on all study days by the same investigator, who was unaware of the results of the dialysis measurements.
A laboratory screening was carried out on all study days and included blood haemoglobin, sedimentation rate, leucocyte count, leucocyte differential count, platelet count, and serum concentrations of creatinine and orosomucoid.
Thus patients completed the trial either (a) after 12 months of passive observation (in cases with normal PGE2 concentrations throughout); (b) six months after randomisation (in case PGE2 concentrations exceeded control levels); or (c) inbetween, if a relapse occurred.
Results obtained in the cohort of randomised patients served to evaluate the primary purpose of the study, that is, to test the predictive value of 'an increase in PGE2 levels' for experiencing a relapse in patients with inactive UC off SAZ treatment. Indirectly, in this design the named cohort also appeared to re-evaluate the efficacy of SAZ in maintaining remission.
IN VIVO DIALYSIS METHODS
Equilibrium in vivo dialysis of faeces was carried out as previously described in detail," by pooling the contents of five swallowed dialysis bags after their intestinal transit (faecal dialysate). These dialysates were analysed for concentrations of PGE2 (faecal PGE2) and leucotriene B4 (faecal LTB4).
Equilibrium in vivo dialysis of rectum was done after insertion of a 12-cm-long dialysis bag into the emptied rectum as previously described."' The bag was left for four hours when it was removed and its contents (rectal dialysate) were analysed for concentrations of PGE2 (rectal PGE2) and leucotriene B4 (rectal LTB4).
ANALYTICAL PROCEDURES
Prostaglandin E2 was measured as previously described in detail'5 by a radioimmunological method validated by gas chromatography mass spectrometry. 16 The method, using 10-100 Id samples, included addition of 3H-labelled PGE2 (Amersham International, Buckinghamshire, UK) as an internal standard, acidification, extraction with ethylacetate/ cyclohexane (1:1), and chromatography on microcolumns of Sephadex LH-20 (Pharmacia AB, Uppsala, Sweden) before performing the radioimmunoassay itself on the eluate fraction. The detection limit, defined as the procedure blank value +2 SD, was 0-03 ng/ml. Leucotriene B4 was measured by using a com- The results were expressed as ng/ml of colonic fluid. In 10 healthy controls the following results have previously been obtained:" 1 ' Faecal PGE2 <0-5 ng/ ml; faecal LTB4 <0-5 ng/ml; rectal PGE2 <0 6 ng/ml; rectal LTB4 <0-5 ng/ml.
STATISTICAL ANALYSIS
Fisher's exact test was used for analysis of four-fold tables.'8 A value of p<0.05 was considered significant.
Results
DESCRIPTION OF PATIENTS
Twenty four patients consecutively entered the trial within an 18 month period. Another three patients fulfilled the entry criteria, but refused participation. One patient recruited for the study was withdrawn because revision of her records showed that she had Crohn's disease. Twelve patients remained non-randomised and ten of these experienced a relapse (Table 3) . Retrospectively: in two cases (both relapsing within two weeks after cessation of SAZ treatment) PGE2 concentrations were increased at entry ( The faecal and rectal LTB4 concentrations were determined in all dialysates. These measurements were not included in the protocol describing the prospective study, why the data were subjected to a retrospective analysis. In most patients the faecal and rectal LTB4 concentrations were below the detection *R, randomisation -that is, in case faecal PGE2 >0.5 ng/ml and/or rectal PGE2 >1.0 ng/ml; tND, not done.
limit (<0.2 ng/ml). Eleven patients were randomised because of abnormally increased PGE2 concentrations (as described above): In six cases the faecal PGE2 concentrations exceeded control levels (0 5 ng/ ml), but only in a single case LTB4 concentrations were raised: in 11 cases rectal PGE2 concentrations exceeded the randomisation level (1.0 ng/ml), but only in five cases simultaneously increased LTB4 levels were observed. Similarly, LTB4 concentrations did not exceed control levels in the patients not randomised.
CLINICAL OUTCOME
The patient distribution and clinical outcome is summarised in the Figure. All relapses were proven by histology of rectal biopsies. In all patients remission was reinstated: In seven cases by resuming SAZ treatment 2-3 glday orally; in six cases by resuming SAZ 2-3 glday orally, in addition to topical treatment with corticosteroids, for two to eight weeks; and in a single case after prolonged treatment with systemic corticosteroid, in addition to SAZ.
Discussion
The present results suggest that an increased PGE2 concentration in rectal dialysis fluid determined by equilibrium in vivo dialysis of rectum heralds a relapse in patients with inactive UC. First, in patients randomised (because of increased PGE2 concentrations) four of five allocated to placebo experienced a relapse. By contrast, six similar patients resuming SAZ remained in remission and at their subsequent visit had shown a decrease toward control levels in Table 3 Faecal and rectal PGE2 concentrations and outcome in 12 patients with inactive ulcerative colitis in whom sulphasalazine was stopped at entry. These patients were observed passively because randomisation to sulphasalazine or placebo was not indicated by the protocol 
